Brown Technology Innovations
Dr. Haass-Koffler Awarded Brown Biomedical Innovation to Impact (BBII) Award
Overdose deaths are increasing, despite efforts by governments to address illicit drug use and implement public health approaches. A significant reason is the increasing prevalence of xylazine (tranq), an alpha-2 adrenergic agonist and central nervous system depressant present in the fentanyl drug supply.
Read Article